

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

**CONVEYING PARTY DATA**

Name	Execution Date
CREDIT SUISSE AG	01/31/2011

**RECEIVING PARTY DATA**

Name:	KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
Street Address:	501 FIFTH STREET
City:	BRISTOL
State/Country:	TENNESSEE
Postal Code:	37620

**PROPERTY NUMBERS Total: 49**

Property Type	Number
Patent Number:	5070877
Patent Number:	5714607
Patent Number:	5939432
Patent Number:	6048865
Patent Number:	6448253
Patent Number:	6323214
Patent Number:	6187746
Patent Number:	6177444
Patent Number:	6194449
Patent Number:	6326390
Patent Number:	6407236
Patent Number:	6368573
Patent Number:	6248774
Patent Number:	6727258
Patent Number:	6489356

**CH \$1960.00 5070877**

Patent Number:	6407128
Patent Number:	7067148
Patent Number:	6555581
Patent Number:	7112607
Patent Number:	6683102
Patent Number:	7101905
Patent Number:	6921825
Patent Number:	7101569
Patent Number:	6951932
Patent Number:	7205403
Patent Number:	7064204
Patent Number:	7511133
Patent Number:	7342003
Patent Number:	7271171
Application Number:	11182661
Application Number:	11259678
Application Number:	11332120
Patent Number:	7435740
Patent Number:	7335655
Patent Number:	7449490
Application Number:	11594535
Application Number:	11729624
Patent Number:	7691825
Application Number:	11767575
Patent Number:	7470698
Application Number:	11872800
Application Number:	11873909
Application Number:	11938465
Application Number:	11938514
Patent Number:	7691869
Application Number:	12056423
Application Number:	12125511
Application Number:	12175711
Application Number:	12437344

**CORRESPONDENCE DATA**

Fax Number: (202)778-6493  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 202-662-6493  
Email: kashton@cov.com  
Correspondent Name: Covington & Burling LLP  
Address Line 1: 1201 Pennsylvania Avenue, N.W.  
Address Line 2: Attn: Patent Docketing  
Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:	029459.00030
-------------------------	--------------

NAME OF SUBMITTER:	Andrea Reister
--------------------	----------------

Total Attachments: 6  
source=King R&D Patent Release#page1.tif  
source=King R&D Patent Release#page2.tif  
source=King R&D Patent Release#page3.tif  
source=King R&D Patent Release#page4.tif  
source=King R&D Patent Release#page5.tif  
source=King R&D Patent Release#page6.tif

**Release of Security Interest in Patents**

**January 31, 2011**

**WHEREAS**, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower, certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated as of May 11, 2010;

**WHEREAS**, pursuant to the GCA, Credit Suisse and King Pharmaceuticals Research and Development, Inc., a Delaware corporation (the “**Assignee**”), entered into that certain Patent Security Agreement dated May 11, 2010 and recorded with the United States Patent and Trademark Office on May 13, 2010 on Reel No. 024382, Frame No. 0208 (the “**Patent Security Agreement**”);

**WHEREAS**, under the Patent Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Patent Collateral (as defined in the Patent Security Agreement), including those items set forth on Schedule 1 hereto (collectively, the “**Released Patent Collateral**”);

**WHEREAS**, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

**WHEREAS**, Credit Suisse desires to release the security interest granted by the Assignee under the Patent Security Agreement in the Released Patent Collateral.


**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Patent Security Agreement in the Released Patent Collateral and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee, without any representation or warranty by, or recourse to, Credit Suisse, all right, title and interest of Credit Suisse in, to and under such Released Patent Collateral granted under the Patent Security Agreement. This Release of Security Interest in Patents shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Patents against the Released Patent Collateral.

*[signature page to follow]*

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Patents to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH

By:   
Name: DOREEN BARR  
Title: DIRECTOR

By:   
Name: VIPUL DHADDA  
Title: ASSOCIATE

*[signature page – King Pharmaceuticals Research and Development, Inc. patent release]*

**Schedule 1**

**KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.**

**PATENTS AND PATENT APPLICATIONS**

<b>Internal Title</b>	<b>Filing #</b>	<b>Grant #</b>	<b>Type<sup>1</sup></b>	<b>Expiration</b>
Novel Method Of Myocardial Imaging	07/330,156	5,070,877	CIP	May 18, 2009
Process Improvement in the Synthesis of N- N-[3-(3-CYANO-PYRAZOLO[1, 5a] PYRIMIDIN-7-Y1)PHENYL]N-ETHYLACETAMIDE	08/758,132	5,714,607	NP	November 25, 2016
Allosteric Adenosine Receptor Modulators	08/959,758	5,939,432	NP	October 29, 2017
N6 Substituted-Adenosine-5'-Uronamides As Adenosine Receptor Modulator	09/124,434	6,048,865	NP	July 29, 2018
Adenosine A3 Receptor Modulators	09/154,435	6,448,253	NP	September 16, 2018
Allosteric Adenosine Receptor Modulators	09/156,077	6,323,214	CIP	October 29, 2017
Pharmaceutical Compositions Based On Dalfopristine and On Quinupristine and Their Preparation	09/210,938	6,187,746	NP	December 15, 2018
Allosteric Adenosine Receptor Modulators	09/307,225	6,177,444	DIV	October 29, 2017
Allosteric Adenosine Receptor Modulators	09/307,286	6,194,449	DIV	October 29, 2017
Use Of Adenosine A3 Receptor Antagonists To Inhibit Tumor Growth	09/377,271	6,326,390	NP	August 19, 2019

<sup>1</sup> Within this chart. the following abbreviations are used with reference to the Type of Patent/ Application:

NP = Non-Provisional  
PSP = Provisional  
DIV = Divisional  
CIP = Continuation-in-Part

CNT = Continuation  
REI = Reissue  
DP = Design Patent

<b>Adenosine A3 Receptor Modulators</b>	09/379,300	6,407,236	CIP	September 16, 2018
<b>Diagnostic Uses Of 2-Substituted Adenosine Carboxamides</b>	09/440,330	6,368,573	NP	November 15, 2019
<b>Method For Treating Hyper-Excited Sensory Nerve Functions In Humans</b>	09/654,994	6,248,774	NP	December 12, 2020
<b>Allosteric Adenosine Receptor Modulators</b>	09/811,679	6,727,258	CIP	October 29, 2017
<b>Method For Treating Hyper-Excited Sensory Nerve Functions In Humans</b>	09/883,474	6,489,356	CIP	December 12, 2020
<b>Method For Increasing The Bioavailability Of Metaxalone</b>	09/998,206	6,407,128	NP	December 3, 2021
<b>Stabilized Pharmaceutical and Thyroid Hormone Compositions and Method Of Preparation</b>	10/076,999	7,067,148	NP	February 15, 2022
<b>Levothyroxine Compositions and Methods</b>	10/077,677	6,555,581	NP	February 15, 2022
<b>Allosteric Adenosine Receptor Modulators</b>	10/101,817	7,112,607	DIV	July 14, 2018
<b>Method For Increasing The Bioavailability Of Metaxalone</b>	10/104,044	6,683,102	CNT	December 3, 2021
<b>Pharmaceutically Active Compounds and Methods Of Use</b>	10/112,613	7,101,905	NP	March 29, 2022
<b>Adenosine A3 Receptor Modulators</b>	10/134,219	6,921,825	CIP	September 16, 2018
<b>Methods Of Administering Levothyroxine Pharmaceutical Compositions</b>	10/218,718	7,101,569	NP	October 2, 2023
<b>Synthesis Of 2-Aralkoxyadenosines and 2-Alkoxyadenosines</b>	10/281,291	6,951,932	NP	April 17, 2023
<b>8-Heteroaryl Xanthine Adenosine A2b Receptor Antagonists</b>	10/357,865	7,205,403	NP	February 3, 2023
<b>Pharmaceutically Active Compounds Having A Tricyclic Pyrazolotriazolopyrimidine Ring Structure and Method Of Use</b>	10/452,788	7,064,204	NP	May 30, 2023
<b>Novel Adenosine A3 Receptor Agonists</b>	10/944,245	7,511,133	NP	September 17, 2024
<b>Synthesis Of 2-Aralkoxyadenosines, 2-Alkoxyadenosines, and Their Analogs</b>	11/155,212	7,342,003	CNT	October 3, 2024

Adenosine A3 Receptor Modulators	11/169,311	7,271,171	DIV	September 16, 2018
Method For Increasing The Bioavailability Of Metaxalone	11/182,661		CNT	December 3, 2021
Method For Increasing The Bioavailability Of Metaxalone	11/259,678		CNT	December 3, 2021
Method Of Myocardial Imaging For Asthmatic Patients	11/332,120		NP	January 12, 2026
Novel Adenosine A3 Modulators	11/344,295	7,435,740	NP	January 31, 2026
8-Heteroaryl Xanthine Adenosine A2b Receptor Antagonists	11/359,661	7,335,655	DIV	February 3, 2023
Pharmaceutically Active Compounds and Methods Of Use	11/402,240	7,449,490	DIV	December 22, 2022
Compositions Of Stabilized Ramipril In Combination With Another Active Agent	11/594,535		NP	November 7, 2026
Pharmaceutical Compositions For Promoting Wound Healing	11/729,624		NP	March 29, 2027
Adenosine A2b Receptor Agonists	11/757,559	7,691,825	NP	June 4, 2027
Adenosine A2b Receptor Antagonists	11/767,575		NP	June 25, 2027
Adenosine A3 Receptor Modulators	11/774,784	7,470,698	DIV	September 16, 2018
Combination Therapy For The Treatment Of Pain	11/872,800		NP	October 16, 2027
Pharmaceutical Compositions For Promoting Wound Healing	11/873,909		CNT	March 29, 2027
Allosteric Modulators Of The A1 Adenosine Receptor	11/938,465		NP	November 12, 2027
Allosteric Modulators Of The A1 Adenosine Receptor	11/938,514		NP	November 12, 2027
Novel Adenosine A2a Receptor Antagonists (Kprd-516) For The Treatment Of Parkinson's Disease	12/056,403	7,691,869	NP	March 27, 2028
Novel Adenosine A2a Receptor Antagonists (Kprd-516) For The Treatment Of Parkinson's Disease	12/056/423		NP	March 27, 2028
Pharmaceutical Formulations For The Treatment Of Pain	12/125,511		NP	May 22, 2028
Crystals of (Amino-4,5,6, 7-Tetrahydrobenzo[B]Thien-3-Y1) (4-Chlorophenyl)Methanone	12/175,711		NP	July 18, 2028
Allosteric Enhancers of the A1 Adenosine Receptor	12/437,344		NP	May 7, 2029



**PATENT LICENSES**

<b>Name of Agreement</b>	<b>Parties (Licensor/Licensee)</b>	<b>Date of Agreement</b>	<b>Subject Matter</b>
License Agreement	New York University / King Pharmaceuticals Research and Development, Inc.	August 29,2008	A2a Receptor Antagonist
License, Development and Commercialization Agreement	Acura Pharmaceuticals, Inc./ King Pharmaceuticals Research and Development, Inc.	October 30, 2007	Acurox and follow-on products
Assignment, Assumption and Consent Agreement	Elan Pharma International Limited and Elan Management Limited/ King Pharmaceuticals Inc. and King Pharmaceuticals Research and Development, Inc.	February 26, 2007	Avinza
Purchase Agreement	Ligand Pharmaceuticals Incorporated/ King Pharmaceuticals, Inc and King Pharmaceuticals Research and Development, Inc.	September 6, 2006	Avinza
Bill of Sale and Assignment and Assumption Agreement	Ligand Pharmaceuticals, Inc. / King Pharmaceuticals Research and Development, Inc.	February 26, 2007	Avinza
Assignment, Assumption and Consent Agreement	Elan Pharma International Limited and Elan Management Limited/ King Pharmaceuticals Inc. and King Pharmaceuticals Research and Development, Inc.	February 26, 2007	Avinza
Development and Commercialization Agreement	Discovery Therapeutics, Inc. / Medco Research, Inc.	August 19,2007	Corvue
Asset Purchase Agreement	Allerex Laboratory Ltd., Anna Maria Solinas Laroche, Rita Fraser, 1055733 Ontario Limited/  King Pharmaceuticals Research and Development, Inc. and 6494871 Canada Ltd.	March 1, 2006	Epi-Pen
Research and License Agreement	New York University /  Medco Research, Inc.	June 1,2006	MRE-0094
Amended and Restated Asset Purchase Agreement	Elan Corporation, plc, Elan Pharma International Limited, Elan Pharmaceuticals, Inc./ King Pharmaceuticals, Inc., Jones Pharma Incorporated, and Monarch Pharmaceuticals, Inc.	May 19,2003	Skelaxin
License Agreement	Vascular Solutions, Inc. / King Pharmaceuticals Research and Development, Inc.	January 9, 2007	Thrombin-JMI